((自动化翻译由路透提供，请见免责声明 ))
11月5日 - ** 医疗技术公司 CeriBell 的 股价上涨 2.4% 至 26.87 美元
** 摩根大通给予CBLL "增持 "评级
** 券商称该公司开发了一种便携式硬件和人工智能驱动的软件，用于诊断和监测医院环境中的非惊厥性癫痫发作患者。
** 摩根大通补充道，CBLL 在高度低渗透的急性护理癫痫发作市场开展业务，该市场价值约 30 亿美元，有拓展新临床适应症的空间。
** 券商将目标价定为 32 美元，较上一交易日收盘价上涨约 22 ** 包括本交易日的走势在内，CBLL 的股价自 10 月份在纳斯达克上市 (link) 以来已经上涨了约 15.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.